- Open
- 530.00
- High
- 550.00
- Low
- 495.00
- Close
- 526.00
- Change
- -30.00 (-5.66%)
- Volume
- 6,712
| 15 Oct 2026 | 16:00:00 | Proposed Retail Offer |
| 15 Oct 2026 | 15:15:00 | Results of Capital Raise |
| 15 Oct 2026 | 07:00:00 | Proposed Capital Raise of New Ordinary Shares to raise not less than £15 million |
| 28 Sept 2026 | 12:00:00 | 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program |
| 25 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 17 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 25 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
4Basebio plc specializes in synthetic enzymatic DNA synthesis for genetic medicines, including cell and gene therapies, DNA and mRNA therapeutics, and vaccines. The company operates a scalable contract manufacturing model, providing GMP-grade synthetic DNA to pharmaceutical and biotech clients transitioning from research to clinical trials and commercialization. With in-house enzyme manufacturing, 4Basebio maintains quality control and rapid product iteration. It serves a diverse customer base of over 125 partners across the biotechnology and pharmaceutical sectors, primarily in the UK and Spain.
| 15 Oct 2026 | 16:00:00 | Proposed Retail Offer |
| 15 Oct 2026 | 15:15:00 | Results of Capital Raise |
| 15 Oct 2026 | 07:00:00 | Proposed Capital Raise of New Ordinary Shares to raise not less than £15 million |
| 28 Sept 2026 | 12:00:00 | 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program |
| 25 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 17 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 25 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
4Basebio plc specializes in synthetic enzymatic DNA synthesis for genetic medicines, including cell and gene therapies, DNA and mRNA therapeutics, and vaccines. The company operates a scalable contract manufacturing model, providing GMP-grade synthetic DNA to pharmaceutical and biotech clients transitioning from research to clinical trials and commercialization. With in-house enzyme manufacturing, 4Basebio maintains quality control and rapid product iteration. It serves a diverse customer base of over 125 partners across the biotechnology and pharmaceutical sectors, primarily in the UK and Spain.
| 28 Sept 2026 | 07:01:00 | Half-year Report |
| 15 Jun 2026 |
| 4basebio appoints Johns Hopkins RNA expert to advisory board |
| 20 May 2026 | AIM movers: MP Evans hit by Indonesian restrictions and CT Automotive improves profit |
| 27 Oct 2025 | AIM movers: Conygar Investment sells land to Stena Line and Bioventix hit by weak China revenues |
| 28 Sept 2026 | 07:01:00 | Half-year Report |
| 15 Jun 2026 |
| 4basebio appoints Johns Hopkins RNA expert to advisory board |
| 20 May 2026 | AIM movers: MP Evans hit by Indonesian restrictions and CT Automotive improves profit |
| 27 Oct 2025 | AIM movers: Conygar Investment sells land to Stena Line and Bioventix hit by weak China revenues |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £285m | -0.4% | |
| £113m | -0.0% | |
4BB4Basebio plc | £82m | -0.3% |
| £38m | +0.3% | |
| £11m | +0.0% | |
| £10m | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £285m | -0.4% | |
| £113m | -0.0% | |
4BB4Basebio plc | £82m | -0.3% |
| £38m | +0.3% | |
| £11m | +0.0% | |
| £10m | -0.2% |
